The RDHL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RDHL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The RDHL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View RDHL Detailed Price Forecast - CNN Money||View RDHL Detailed Summary - Google Finance|
|View RDHL Detailed Summary - Yahoo! Finance||View RDHL Stock Research & Analysis - Zacks.com|
|View RDHL Trends & Analysis - Trade-Ideas||View RDHL Major Holders - Barrons|
|View RDHL Call Transcripts - NASDAQ||View RDHL Breaking News & Analysis - Seeking Alpha|
|View RDHL Annual Report - CompanySpotlight.com||View RDHL OTC Short Report - OTCShortReport.com|
|View RDHL Fundamentals - TradeKing||View RDHL SEC Filings - Bar Chart|
|View Historical Prices for RDHL - The WSJ||View Performance/Total Return for RDHL - Morningstar|
|View the Analyst Estimates for RDHL - MarketWatch||View the Earnings History for RDHL - CNBC|
|View the RDHL Earnings - StockMarketWatch||View RDHL Buy or Sell Recommendations - MacroAxis|
|View the RDHL Bullish Patterns - American Bulls||View RDHL Short Pain Metrics - ShortPainBot.com|
|View RDHL Stock Mentions - StockTwits||View RDHL Stock Mentions - PennyStockTweets|
|View RDHL Stock Mentions - Twitter||View RDHL Investment Forum News - Investor Hub|
|View RDHL Stock Mentions - Yahoo! Message Board||View RDHL Stock Mentions - Seeking Alpha|
|View Insider Transactions for RDHL - SECform4.com||View Insider Transactions for RDHL - Insider Cow|
|View RDHL Major Holdings Summary - CNBC||View Insider Disclosure for RDHL - OTC Markets|
|View Insider Transactions for RDHL - Yahoo! Finance||View Institutional Holdings for RDHL - NASDAQ|
|View RDHL Stock Insight & Charts - FinViz.com||View RDHL Investment Charts - StockCharts.com|
|View RDHL Stock Overview & Charts - BarChart||View RDHL User Generated Charts - Trading View|
RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
Posted on Thursday September 20, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday, Oct. 2, 2018, at 10:30 a.m. ET, at the Sofitel Hotel in New York City.
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
Posted on Wednesday September 12, 2018
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome, one of the most common gastrointestinal disorders In light ...
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
Posted on Thursday September 06, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that the ongoing single-arm Phase IIa study with orally-administered YELIVA® (opaganib, ABC294640)1 for the treatment of advanced cholangiocarcinoma (bile duct cancer) has achieved its pre-specified efficacy goal for the first stage of the two-stage study design, and as a result, the study will continue to its second stage, enrolling the full cohort of 39 evaluable patients. The primary efficacy endpoint of the study is defined as either partial or complete response, or stable disease at four months treatment with YELIVA®.
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
Posted on Tuesday September 04, 2018
Top-line results from the randomized, double-blind confirmatory Phase III study with TALICIA ® are expected before year’ s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection ...